-+ 0.00%
-+ 0.00%
-+ 0.00%
Hailier announced that Qingdao Hengning Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, has completed the construction and equipment installation and commissioning of the main project with an annual output of 6,000 tons and an annual output of 3,000 tons of biphenylpyrimidine. Recently, the trial production plan was reviewed and approved by experts and filed by the relevant competent authorities. It meets the trial production conditions, and will officially enter the trial production stage. The above projects are some product projects after the changes and adjustments of the company's Qingdao Hengning Biology Phase II project.
Share
Listen to the news
Hailier announced that Qingdao Hengning Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, has completed the construction and equipment installation and commissioning of the main project with an annual output of 6,000 tons and an annual output of 3,000 tons of biphenylpyrimidine. Recently, the trial production plan was reviewed and approved by experts and filed by the relevant competent authorities. It meets the trial production conditions, and will officially enter the trial production stage. The above projects are some product projects after the changes and adjustments of the company's Qingdao Hengning Biology Phase II project.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending